IPF is our main treatment for the immunotherapy program for Cancer and HIV. It is a protein-based solution that binds with tumor antigens to create a antigen response on Cancer and in the case of HIV, it prevents the entrance of CD4 T-cells.

IPF for the treatment of Cancer

Immunotherapy has the potential to provide an alternative and/or complementary treatment for most types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.

Unfortunately the immune system by itself can´t recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.

IPF proteins attach to tumor antigens, creating superantigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.

It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.

This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent – fraction and/or its proteins that can attach, serve as the immunogen are already known.

 IPF for the treatment of HIV/AIDS

IPF works as a powerful immune therapy for the treatment of HIV, here are some of its characteristics:

•  Unique, patent-protected HIV and AIDS therapy
•  Turns on the immune system to fight HIV infections not currently achieved with other treatments.
•  Inhibits the infection of CD4 T-cells by HIV
•  Raises CD4 T-cell counts to healthier levels
•  Reduces HIV viral loads

How does it work? Two modes of action 

1. Directly prevents HIV from infecting CD4 T-cells:  By binding to specific proteins on the outer surface of HIV particles, IPF directly prevents HIV from infecting CD4 T-cells
2. Activates the TH1 immune response i.e, turns on macrophages that actually ingest HIV itself, killing the T-lymphocytes that destroy HIV-infected cells and other HIV-fighting immune system responses: Immunotech ipf binds to t-cells and turns on th1 immune system responses that kill hiv and hiv infected cells

Currently its the only HIV/AIDS therapy in the market capable of achieving it.

Antiretroviral therapies have serious limitations

• HIV infections are most treatable during its earlier stages
• Patients cannot take antiretrovirals during earlier stages, since drug resistance often develops
• Limited or no treatment options exist when viral load and CD4 cell counts are at their worst, i.e,  AIDS.
• Non-antiretroviral treatments like IPF remain lacking but are in tremendous demand.

Life Choice IPF advantages

• Replaces or complements current antiretroviral therapies
• Potentially lesser costly and much less toxic
• May be effective as a periodic therapy instead of a daily one
• Likely unaffected by HIV mutations that can hamper antiretroviral therapies (HAART)